Bristol Myers Squibb Canada Co. Sustainability Profile
Bristol Myers Squibb Canada Co., a subsidiary of the renowned global biopharmaceutical company Bristol Myers Squibb, is headquartered in Canada and operates extensively across the country. Founded in 1887, the company has established itself as a leader in the pharmaceutical industry, focusing on innovative medicines in areas such as oncology, immunology, and cardiovascular disease. Bristol Myers Squibb is known for its commitment to research and development, with core products that include groundbreaking therapies like Opdivo and Eliquis, which have transformed treatment paradigms. The company’s dedication to advancing science and improving patient outcomes has positioned it as a key player in the Canadian healthcare landscape. With a strong emphasis on collaboration and innovation, Bristol Myers Squibb continues to achieve notable milestones in the fight against serious diseases.
DitchCarbon Score
How does Bristol Myers Squibb Canada Co.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Bristol Myers Squibb Canada Co.'s score of 71 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Bristol Myers Squibb Canada Co. currently does not have specific carbon emissions data available for the most recent year. However, the company is part of a broader corporate family that includes Bristol-Myers Squibb Company, which provides emissions data and climate commitments at a higher level. As a current subsidiary of Bristol-Myers Squibb Company, Bristol Myers Squibb Canada Co. inherits significant climate initiatives and targets. The parent company has committed to various sustainability efforts, including participation in the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP). These initiatives aim to reduce greenhouse gas emissions across all scopes, although specific reduction targets for Bristol Myers Squibb Canada Co. have not been detailed. Bristol Myers Squibb Company has also engaged in initiatives such as RE100 and the Responsible Business Alliance, which focus on renewable energy and responsible sourcing, respectively. While specific emissions figures for Bristol Myers Squibb Canada Co. are not available, the overarching commitments from the parent company reflect a strong dedication to addressing climate change and reducing carbon footprints. In summary, while Bristol Myers Squibb Canada Co. does not report specific emissions data, it is aligned with the climate commitments and reduction initiatives of its parent company, Bristol-Myers Squibb Company, which actively works towards sustainability and emission reductions.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 210,540,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 150,790,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 69,630,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 00,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Bristol Myers Squibb Canada Co.'s Industry?
How Carbon Intensive is Bristol Myers Squibb Canada Co.'s Location?
Bristol Myers Squibb Canada Co.'s Scope 3 Categories Breakdown
Bristol Myers Squibb Canada Co.'s Scope 3 emissions, which decreased by 1% last year and increased significantly since 2015, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 77% of Scope 3 emissions.
Top Scope 3 Categories
Bristol Myers Squibb Canada Co.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Bristol Myers Squibb Canada Co. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
